MedPath

Efficacy and safety of a single intracavernous injection of autologous adipose-derived stem cells for post radical prostatectomy erectile dysfunctio

Not Applicable
Conditions
Erectile Dysfunction
Registration Number
JPRN-UMIN000050898
Lead Sponsor
Al Zahraa Hospital
Brief Summary

Following ADSCs administration, the EF was improved in all patients of the treatment group. One month after therapy, all of the patients in the treatment group had an increase in their IEF-5 score. At 6 and 12 months, in this group, the degree of ED was moderate in 3 patients and mild in 4 patients. In the control group, for patients treated only with PDE5i, the ED remains severe all the time No significant side effects were reported by the patients after ADSCs injections

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
14
Inclusion Criteria

Not provided

Exclusion Criteria

Impotent males before RP

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Erectile function (EF) was tested using the IIEF-5 score after intracorporal injection of ADSCs
Secondary Outcome Measures
NameTimeMethod
Assess safety of ADSC therapy
© Copyright 2025. All Rights Reserved by MedPath